Sitryx Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, announced its management will participate in three key investor conferences in June 2026: Jefferies Global Healthcare Conference in New York, J.P. Morgan European Healthcare Forum in London, and Evercore Emerging Private Biotech Conference in Newport. These events provide opportunities for one-on-one and group meetings with investors, highlighting Sitryx's ongoing efforts to advance its novel oral therapies, including its lead candidate SYX-5219. Participation in these conferences aims to increase investor engagement and support for Sitryx's pipeline development and future clinical progress.
China Automotive Systems has begun volume shipments of its electric power steering (EPS) systems to a global automaker's European division. This marks a significant milestone as the EPS models will be used in two new vehicle models in Europe, with an...
Auddia Inc. spotlighted the AI infrastructure opportunity of its LT350 subsidiary, referencing a $1.25 billion GPU cloud contract by SharonAI as a market benchmark. LT350's patented design uses parking lot airspace to deploy up to 960,000 GPUs, poten...
Heineken N.V. has repurchased 2,543,263 shares under the second €750 million tranche of its €1.5 billion share buyback program as of May 15, 2026. The shares were bought both on the exchange and from Heineken Holding N.V., with an average price of €6...
Florida Atlantic University's Executive Education Programs have been ranked No. 1 in Florida and No. 4 in the U.S. by the Financial Times for their professional development offerings. The program provides over 60 certifications and caters to working ...
Crédit Agricole Brie Picardie conducted share buybacks from May 11 to May 15, 2026, under Article 5 of the MAR regulation. The bank repurchased a total of several thousand shares daily at prices ranging from approximately €33.27 to €34.98 on the XPAR...
